GLP-2
Dual incretin axis agonist engaging both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptors simultaneously. Studied in metabolic research for additive or synergistic incretin signalling through Gs-coupled cAMP pathways in pancreatic and hypothalamic tissue.
Mechanism of Action
This compound functions as a dual agonist at the GIP receptor (GIPR) and the GLP-1 receptor (GLP-1R), two class B1 G protein-coupled receptors that serve as the principal targets of the incretin hormonal axis. Both receptors signal primarily through Gs-coupled adenylyl cyclase activation, leading to intracellular cAMP elevation and downstream protein kinase A (PKA) activation. The simultaneous engagement of both receptors is the defining pharmacological characteristic studied in metabolic research models.
GIP receptor agonism is studied for its direct effects on pancreatic beta-cells, where GIPR activation potentiates glucose-stimulated insulin secretion in a glucose-dependent manner. GIPR is also highly expressed in adipocytes, where GIP signalling is studied for effects on lipid metabolism including adipocyte lipid uptake and lipolysis inhibition. The GIP axis interacts with the hypothalamus, where GIPR expression has been documented and its role in energy balance signalling studied.
GLP-1 receptor agonism is among the most extensively characterised mechanisms in contemporary metabolic pharmacology. GLP-1R activation on pancreatic beta-cells produces glucose-dependent insulin secretion enhancement and suppression of glucagon release from alpha-cells. Central GLP-1R activation — particularly in the hypothalamic arcuate nucleus and brainstem — is studied for appetite suppression and gastric motility reduction effects. The combination of both receptor pathways is studied for whether dual engagement produces additive or synergistic outcomes relative to single-receptor agonism.
Adipose tissue is a key site where the combination of GIPR and GLP-1R signalling is studied, given that both receptors are expressed in adipocytes and their respective cAMP pathways modulate lipolytic enzyme activity and lipid storage dynamics.
Key Research Findings
- GIP receptor agonism has been studied for direct pancreatic insulinotropic effects, with GIPR expression in pancreatic beta-cells confirmed across multiple research systems, alongside documented roles in adipocyte lipid metabolism modulation. Baggio & Drucker, Gastroenterology, 2007.
- GLP-1 receptor agonism is extensively documented for beta-cell insulin secretion enhancement in a glucose-dependent manner, along with gastric motility reduction — effects that have been characterised across decades of incretin pharmacology research. Drucker & Nauck, The Lancet, 2006.
- Combined GIP+GLP-1 receptor engagement has been studied for greater glucose-lowering and body composition research outcomes compared to single-receptor engagement alone, with published data examining whether the dual pathway produces additive or synergistic Gs-cAMP signalling in pancreatic and hypothalamic tissue. Frías et al., New England Journal of Medicine, 2021 (SURPASS-2).
- Hypothalamic receptor distribution of both GIPR and GLP-1R has been documented in neuroanatomical research, providing the mechanistic basis for studying central appetite modulation through dual incretin pathway activation. Central incretin receptor neuroanatomy literature, 2010s.
- Preclinical models examining dual receptor pathway activation have described significant adiposity reduction outcomes, with adipose tissue signalling studied as a primary endpoint for the combined receptor mechanism. Coskun et al., Molecular Metabolism, 2018.
Citations last reviewed: 1 October 2026
As Supplied by BasedPeps
Researcher FAQ
What is the GLP-2 dual incretin research compound?
GLP-2 in this research context refers to a dual incretin agonist engaging both the GIP receptor (GIPR) and the GLP-1 receptor (GLP-1R) simultaneously. It is studied as a tool compound for investigating dual incretin axis signalling in metabolic research models, including pancreatic beta-cell function and hypothalamic appetite regulation.
How does dual GIP+GLP-1 agonism differ from single GLP-1 agonism in research models?
Single GLP-1 receptor agonists engage only the GLP-1R pathway, primarily studied for insulinotropic and anorectic effects. Dual GIP+GLP-1 agonism additionally activates GIPR-mediated signalling in adipocytes and pancreatic tissue, with published research suggesting additive or synergistic metabolic outcomes compared to GLP-1R engagement alone. The GIPR component introduces an additional adipocyte signalling axis not present in monotherapy GLP-1R research designs.
How is this compound stored and reconstituted for research use?
Supplied as lyophilised powder, stored at −20 °C. Reconstitution is performed in sterile bacteriostatic water, gently swirling until dissolved. Concentration is determined by experimental protocol. Reconstituted solution is stored at 2–8 °C and used within 28 days. Repeated freeze-thaw cycles of reconstituted material should be minimised.
What research category does this compound belong to?
This compound is classified under metabolic research. Investigational areas include dual incretin axis pharmacology, pancreatic endocrinology, adipocyte biology, and hypothalamic appetite circuit research.
Does BasedPeps provide purity documentation?
Yes. Every BasedPeps lot includes a third-party Certificate of Analysis documenting HPLC purity (≥99%) and mass spectrometric identity confirmation. Certificates of Analysis are available per batch on request.
View BasedPeps GLP-2
Research-grade dual incretin agonist. Third-party HPLC and mass spectrometry verification per lot. Certificate of Analysis available on request. Dispatched from Riga, Latvia within 24 hours.
View BasedPeps GLP-2 →